‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use - Takeaways - MDSpire
Commentary & Perspectives

‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...

  • By

  • Caroline Helwick

  • May 6, 2026

  • 8 min

Share

  • 1

    ctDNA shows promise in treating early-stage breast cancer but lacks proven efficacy.

  • 2

    Strong association between ctDNA and distant recurrence exists.

  • 3

    Caution in clinical application is advised until evidence from interventional trials emerges.

  • 4

    Current tests of ctDNA do not conclusively guide treatment decisions.

  • 5

    Future studies are needed to establish ctDNA's clinical utility in practice.

Original Source(s)

‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

  • by Caroline Helwick

  • May 6, 2026

Related Content

One Pathway for Esophageal Cancer?

Molecular profiling reveals precursor signals in BE-negative esophageal cancer

  • May 7, 2026

  • 2 min
Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...

Experimental Daraxonrasib Shows Promise in Advanced Pancreatic Cancer

Metastatic pancreatic ductal adenocarcinoma remains one of the most challenging malignancies to treat in clinical oncology.

  • by

  • May 6, 2026

  • 5 min